Berg, David D <br/><br/>
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.  [electronic resource] 

 -  Circulation  11 2019 
 - 1569-1577 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Study 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/CIRCULATIONAHA.119.042685  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--analogs & derivatives<br/>Aged<br/>Benzhydryl Compounds--adverse effects<br/>Clinical Decision-Making<br/>Decision Support Techniques<br/>Diabetes Mellitus, Type 2--complications<br/>Diabetic Cardiomyopathies--diagnosis<br/>Dipeptides--therapeutic use<br/>Dipeptidyl-Peptidase IV Inhibitors--therapeutic use<br/>Female<br/>Glucosides--adverse effects<br/>Health Status<br/>Heart Failure--diagnosis<br/>Humans<br/>Male<br/>Middle Aged<br/>Patient Selection<br/>Predictive Value of Tests<br/>Randomized Controlled Trials as Topic<br/>Reproducibility of Results<br/>Risk Assessment<br/>Risk Factors<br/>Sodium-Glucose Transporter 2 Inhibitors--adverse effects<br/>Time Factors<br/>Treatment Outcome